Pages that link to "Q67209091"

The following pages link to Amantadine dosage in treatment of Parkinson's disease (Q67209091):

Displaying 36 items.

• Amantadine in Parkinson's disease (Q24250281) (← links)
• Amantadine-induced heart-failure (Q28318048) (← links)
• Acute psychosis after amantadine overdose (Q28335085) (← links)
• Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults (Q28367038) (← links)
• Clinical pharmacokinetics of amantadine hydrochloride. (Q34172068) (← links)
• Economic and health-related quality of life considerations of new therapies in Parkinson's disease (Q34363332) (← links)
• Assessment of extrapyramidal disorders (Q34448515) (← links)
• Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments (Q34622392) (← links)
• Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study (Q35910081) (← links)
• Amantadine aerosols in normal volunteers: pharmacology and safety testing (Q36485705) (← links)
• Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment (Q39456220) (← links)
• Clinical pharmacokinetics of anti-parkinsonian drugs (Q39673262) (← links)
• The Management of Parkinson's Syndrome (Q39915783) (← links)
• Augmenting the action of levodopa (Q39922539) (← links)
• Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects (Q39992490) (← links)
• Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective (Q40627732) (← links)
• The comparative value of amantadine and levodopa (Q41250808) (← links)
• ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study (Q41824342) (← links)
• Treatment of Parkinson's disease with amantadine and levodopa. A one-year study (Q42230357) (← links)
• Amantadine therapy in parkinsonism (Q42233432) (← links)
• Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (Q46641045) (← links)
• Amantadine in Parkinsonism. (Q54419170) (← links)
• Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. (Q55285379) (← links)
• Parkinsonism-physiology and pharmacology. (Q55347683) (← links)
• NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. (Q55474333) (← links)
• EXTRAPYRAMIDAL SIGNS IN DEMENTIA OF ALZHEIMER TYPE (Q60347848) (← links)
• An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used in combination in Parkinson's Disease (Q64869777) (← links)
• Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy (Q64869779) (← links)
• Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. (Q64869994) (← links)
• Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects (Q64895720) (← links)
• Amantadine and L-Dopa (Q64902830) (← links)
• Treatment for Parkinsonism, other than levodopa (Q64916153) (← links)
• Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial (Q67207847) (← links)
• Effect of add-on amantadine therapy for refractory absence epilepsy (Q67580379) (← links)
• A risk-benefit assessment of drugs used in the management of Parkinson's disease (Q72768879) (← links)
• Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies (Q92360533) (← links)